We have initiated a program with the intention of overcoming the problem of short biological half-life of these peptides, and in our previous reports, 1 we described our work on peptide backbone modification that led to the demonstration of an orally active renin inhibitory peptide. The present study reports a variant of this approach that has resulted in enzyme inhibitors with comparable biological half-life. It is our conviction that a focus on in vivo ...